Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,769 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,436 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,347)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07052994 | A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and Relapsed /Refractory Pediatric Acute Leukemia Patients | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Sep 23, 2026 | clinicaltrials |
| NCT06597734 | A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER |
| 0 |
| Sep 11, 2026 |
| clinicaltrials |
| NCT07566585 | Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation | withdrawn | Phase 1 | 0 | BlueSphere Bio, IncINDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07338357 | Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML | withdrawn | Early Phase 1 | 0 | First Affiliated Hospital of Guangxi Medical UniversityOTHER | 0 | Aug 26, 2026 | clinicaltrials |
| NCT06703216 | Pre-emptive Anakinra for Cytokine Event Reduction(PACER) | withdrawn | Phase 1 / Phase 2 | 0 | Kevin McNerneyOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT06903702 | A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid Leukemia | withdrawn | Phase 2 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 0 | Aug 5, 2026 | clinicaltrials |
| NCT07084584 | ENLIGHT-AML - An Open-label, Study of GB3226 in Patients With Relapsed/Refractory Acute Myeloid Leukemia | withdrawn | Phase 1 | 0 | Galecto Biotech ABINDUSTRY | 0 | Jul 6, 2026 | clinicaltrials |
| NCT02903277 | National Observatory of Chronic Myeloid Leukemia Adolescent and Young Adults Treated With Tyrosine Kinase Inhibitors in First Intent | withdrawn | — | 0 | Centre Hospitalier Universitaire de NiceOTHER | 0 | Jun 16, 2026 | clinicaltrials |
| NCT07123662 | γδ T Cell Therapy for Relapse Prevention in High-Risk AML Post-Transplant | withdrawn | Early Phase 1 | 0 | Guangzhou Bio-gene Technology Co., LtdINDUSTRY | 0 | May 28, 2026 | clinicaltrials |
| NCT06522373 | Phase I Trial of MT-0169 in CD38+ Acute Leukemia With Relapsed/Refractory or Measurable Residual Disease | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | May 15, 2026 | clinicaltrials |
| NCT07585734 | Clinical Trial of CD38 Monoclonal Antibody Combined With Chemotherapy for T-Cell Acute Lymphoblastic Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | May 14, 2026 | clinicaltrials |
| NCT06570915 | Daratumumab for T Cell ALL With MRD-positive After Standard Chemotherapy(T-ALL-2024) | withdrawn | Phase 2 | 0 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | May 13, 2026 | clinicaltrials |
| NCT05909527 | A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | Guangzhou Bio-gene Technology Co., LtdINDUSTRY | 1 | Mar 17, 2026 | clinicaltrials |
| NCT04953312 | Calprotectin, a Biomarker of COVID-19 Severity (CALPRO)(CALPRO) | withdrawn | N/A | 0 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT05170828 | Cryopreserved MMUD BM With PTCy for Hematologic Malignancies | withdrawn | Phase 1 | 0 | Ossium Health, Inc.INDUSTRY | 0 | Feb 24, 2026 | clinicaltrials |
| NCT07071909 | Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells | withdrawn | Phase 1 / Phase 2 | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT02315157 | Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma | withdrawn | Phase 1 | 0 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Oct 15, 2025 | clinicaltrials |
| NCT06009107 | A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL)(B-ALL) | withdrawn | Phase 1 / Phase 2 | 0 | Juventas Cell Therapy Ltd.INDUSTRY | 0 | Aug 8, 2025 | clinicaltrials |
| NCT06474663 | A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating With Decitabine in Pediatric Relapsed and Refractory Acute Leukemias | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Aug 6, 2025 | clinicaltrials |
| NCT05968170 | TCRαβ/CD19 Depletion of Stem Cell Grafts for Transplant | withdrawn | N/A | 0 | Neena Kapoor, M.D.OTHER | 0 | Jul 14, 2025 | clinicaltrials |
| NCT06013904 | Difficult PIV Placement in the Pediatric ED | withdrawn | N/A | 0 | University of Texas at AustinOTHER | 0 | Jul 4, 2025 | clinicaltrials |
| NCT07046481 | Physical Activity and Quality of Life in Childhood Cancersurvivors- a Long-term Follow-up | withdrawn | N/A | 0 | Region SkaneOTHER | 0 | Jul 1, 2025 | clinicaltrials |
| NCT05521087 | A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias | withdrawn | Phase 1 | 0 | Janssen Research & Development, LLCINDUSTRY | 0 | Jun 22, 2025 | clinicaltrials |
| NCT05248685 | Optimized Dual CD33/CLL1 CAR T Cells in Subjects With Refractory or Relapsed Acute Myeloid Leukemia | withdrawn | Phase 1 | 0 | Beijing Boren HospitalOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT06770257 | Daunorubicin, Cytarabine Liposomes Plus Venetoclax vs Azacitidine Plus Venetoclax in AML Patients Unfit for Intensive Chemotherapy | withdrawn | Phase 2 | 0 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Jun 3, 2025 | clinicaltrials |
| NCT04685915 | Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL | withdrawn | Phase 2 | 0 | Inhye AhnOTHER | 0 | May 22, 2025 | clinicaltrials |
| NCT04694560 | A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | withdrawn | — | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT04556266 | A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 Malignancies | withdrawn | Phase 1 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT03560908 | Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation | withdrawn | Phase 1 | 0 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT05595135 | Mobile Intervention to Improve Adherence of Oral Anti-cancer Medications Among Acute Myeloid Leukemia Patients, the txt4AML Study | withdrawn | N/A | 0 | Thomas Jefferson UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT06351306 | DEC-C and Thioguanine for R/R AML | withdrawn | Phase 2 | 0 | Columbia UniversityOTHER | 0 | Mar 24, 2025 | clinicaltrials |
| NCT06113289 | A Phase 1B/2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Mar 12, 2025 | clinicaltrials |
| NCT04781855 | Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Feb 28, 2025 | clinicaltrials |
| NCT02743546 | Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma | withdrawn | Phase 1 | 0 | Janssen Research & Development, LLCINDUSTRY | 0 | Feb 3, 2025 | clinicaltrials |
| NCT06200441 | Correlation of Serum Gasdermin-D and NLRP-3 Inflammasome Levels With GVHD Biomarkers and Endothelial Damage Markers in Graft-Versus-Host Disease | withdrawn | — | 0 | Ugur Arzu KuluOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT04808115 | IIT PH1 KDS-1001 in Patients With CML | withdrawn | Phase 1 | 0 | Duke UniversityOTHER | 0 | Nov 26, 2024 | clinicaltrials |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs | withdrawn | — | 0 | Travera IncINDUSTRY | 0 | Nov 25, 2024 | clinicaltrials |
| NCT05266950 | Safety and Efficacy Study of CI-135 CAR-T Cells in Subjects with Relapsed or Refractory Acute Myeloid Leukemia | withdrawn | Phase 1 | 0 | Beijing Boren HospitalOTHER | 1 | Nov 14, 2024 | clinicaltrials |
| NCT04521946 | Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Oct 26, 2024 | clinicaltrials |
| NCT04523623 | Pain Control Differences Between Oxycodone and Ibuprofen in Children With Isolated Forearm Injuries | withdrawn | N/A | 0 | Washington University School of MedicineOTHER | 0 | Oct 26, 2024 | clinicaltrials |
| NCT05521178 | Cardiotoxicities in Patients Receiving BTKi | withdrawn | — | 0 | Dana-Farber Cancer InstituteOTHER | 0 | Oct 15, 2024 | clinicaltrials |
| NCT02298816 | B-Cell Hematologic Malignancy Vaccination Registry(HMvax-Regist) | withdrawn | — | 0 | Wake Forest University Health SciencesOTHER | 1 | Oct 3, 2024 | clinicaltrials |
| NCT04982354 | Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | Guenther KoehneOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT04322084 | Continuous Ambulatory Monitoring to Predict Elevated Risk of Infection in Children With Lymphoblastic Leukemia Undergoing Induction Chemotherapy (CAMPER-ALL) | withdrawn | — | 0 | St. Jude Children's Research HospitalOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT01174615 | Collection of Blood and/or Bone Marrow for Investigation and Characterization of Normal and Abnormal Cell Growth | withdrawn | — | 0 | University of Massachusetts, WorcesterOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05823480 | Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 0 | Sep 19, 2024 | clinicaltrials |
Data updated 4 days agoSource updated Sep 23, 2026source: clinicaltrials